JY BioMed ADC Technology Wins Innovation Award, Eyes Global Licensing. Taiwan's JY BioMed has earned the 22nd National Innovation Award for its HCAb-ADC platform, secured FDA Orphan Drug Designation for pancreatic cancer, and published findings in Cancer Letters, as it advances international licensing partnerships across lung, pancreatic, and colorectal cancers.

🌸 Week 2 Mother's Day Challenge — Win Another Premium Skincare Gift! 🎉 Friends who joined last week, listen up! You have another chance this week to win a bottle from the iV Angel Angel Series, sponsored by YC Biotech 🌟 Limited quantities — while supplies last! Join us in celebrating the moms who mean the world to us. 🌸

Celebrate Mother's Day with JY BioMed and YC Biotech! Complete simple social media tasks to win a premium iV Angel skincare gift — serum or cream valued up to NT$5,280. Limited quantities available. Campaign runs April 30 – May 4. Don't miss out!

JY BioMed announces dual FDA Type II Drug Master File acceptance in January 2025, covering UC-MSC and UC-MSC-derived Exosomes. Establishing a fully traceable, vertically integrated regulatory platform, JY BioMed is advancing toward IND submission and positioning as an early leader in the exosome therapeutics space.

Discover how Dr. Ethan Shen, Founder & Chairman of JY BioMed, merges spiritual practice with biotech innovation — driven by a vow to advance cancer immunotherapy research in Taiwan and beyond.

From a small pharmacy in Wanhua, Dr. Ethan Shen led JY BioMed into cell therapy and regenerative medicine—advancing biotech innovation and new possibilities in cancer treatment.

JY BioMed Co., Ltd. is proud to announce the publication of its latest research in the internationally renowned journal Cancer Letters, highlighting a novel antibody-drug conjugate (ADC) platform targeting CEACAM6 for the treatment of aggressive cancers, including brain metastases.

JY BioMed Co., Ltd. is proud to announce the publication of its latest research in the internationally renowned journal Cancer Letters, highlighting a novel antibody-drug conjugate (ADC) platform targeting CEACAM6 for the treatment of aggressive cancers, including brain metastases.

Ji Yan Biomedical Co., Ltd. (JY BioMed), a biotechnology company focused on next-generation cell-based immunotherapies, today announced the publication of a landmark preclinical study demonstrating the potent antitumor activity of unmodified gamma delta (γδ) T cells in hepatocellular carcinoma (HCC).

Ji Yan Biomedical Co., Ltd. (JY BioMed) today announced that the U.S. Food and Drug Administration (FDA) has completed its review of the Company’s Investigational New Drug (IND) application for Stemis™, an investigational mesenchymal stem cell (MSC) therapy, and has issued a “Study May Proceed” notification. This clearance allows JY BioMed to initiate its Phase 1 clinical trial evaluating Stemis™ in elderly participants with mild to moderate frailty syndrome.

JY BioMed (集研生醫股份有限公司) , a biotechnology company dedicated to advancing next-generation immunology and regenerative science, announced the successful presentation of its latest preclinical research programsat the 2025 Healthcare+ Expo Taiwan, held from December 4–7 at the Taipei Nangang Exhibition Center.

JY BioMed Co., Ltd. (集研生醫股份有限公司) and YC Biotech Co., Ltd. (昱君生技股份有限公司) have jointly submitted a Pre-Investigational New Drug (Pre-IND) Meeting request to the U.S. Food and Drug Administration (FDA) for ExoVeris™, an exosome-based therapeutic candidate, marking another important step forward in the international development of Taiwan’s regenerative medicine sector.

JY BioMed Co., Ltd. (集研生醫股份有限公司) and YC Biotech Co., Ltd. (昱君生技股份有限公司) jointly announced that they have officially submitted a Pre-Investigational New Drug (Pre-IND) Meeting request to the Center for Biologics Evaluation and Research (CBER) of the U.S. Food and Drug Administration (FDA) for Stemis™, a human umbilical cord-derived mesenchymal stem cell (hUC-MSC) therapy.

The 2025 conference was jointly organized by Hanoi Medical University Hospital, Binh Duong General Hospital, Da Nang General Hospital, Gia Lai General Hospital, and Ha Giang General Hospital in Tuyen Quang Province, representing the pinnacle of Vietnam’s public healthcare system. Dr. Zhang joined an elite panel of international experts, including Prof. Wu-Hsiu Chang from Show Chwan Healthcare System, Dr. Ching-Tsung Tseng from AIM (Asia’s leader in AI medical diagnostics), an

JY BioMed (Ji Yan Biomedical Co., Ltd.), a biotechnology company focused on next-generation immuno-oncology therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its investigational therapy, an anti-CEACAM6 humanized heavy chain antibody-drug conjugate (HCAb-ADC), for the treatment of pancreatic cancer.

Benzodiazepines (Diazepam) and related Z-drugs (Zolpidem), henceforth referred to as BZDRs, are widely used for clinical treatment of insomnia and anxiety disorders. BZDRs act on GABA type A receptors to inhibit neurotransmitters. We previously demonstrated that prolonged clinical use of BZDRs exacerbates the risk of breast cancer (BRCA).

Natural killer (NK) cells are a critical component of the human innate immune system. As their name implies, NK cells possess the natural ability to detect and destroy virus-infected and malignant cells without prior sensitization or antigen-specific priming. This rapid response mechanism positions them as one of the body’s first lines of defense against disease.

γδ T cells represent a unique and powerful subset of T lymphocytes that combine features of both innate and adaptive immunity. Unlike the conventional αβ T cells that require antigen presentation via MHC molecules, γδ T cells recognize stress-induced ligands in an MHC-independent manner—making them highly effective against malignancies, infections, and even chronic inflammatory conditions.

JY BioMed is pleased to announce that, in collaboration with our clinical development partner YC Biotech, we have officially initiated preparations for a stem cell-based clinical trial targeting Alzheimer’s disease at Taipei Medical University. The trial protocol has been commissioned and is progressing steadily toward regulatory submission and formal IRB review.

JY BioMed today announced that the U.S. Food and Drug Administration (FDA) has granted Investigational New Drug (IND) clearance for its umbilical cord-derived mesenchymal stem cell (UC-MSC) program. The clearance, issued by the Center for Biologics Evaluation and Research (CBER), allows the company to proceed with a first-in-human study under IND number 031083.0.